| HOME >> MEDICINE >> TECHNOLOGY |
Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.
OMCL-EOmnicell, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)Three Months EndedYear EndedDecember 31, 2010(unaudited)September 30, 2010(unaudited)December 31, 2009(unaudited)December 31, 2010(unaudited)December 31, 2009 (1)Revenues:Product$
43,541$
43,241$
42,936$
171,100$
170,068Services and other revenues13,72713,04511,71751,30743,389Total revenue57,26856,28654,653222,407213,457Cost of revenues:Cost of product revenues18,64919,44920,47476,37280,016Cost of services and other revenues7,2566,6986,95628,07927,011Restructuring charges—39—391,209Total cost of revenues25,90526,18627,430104,490108,236Gross profit31,36330,10027,223117,917105,221Operating expenses:Research and development5,4036,0894,03721,00717,569Selling, general, and administrative24,43819,85121,80786,22785,668Restructuring charges—1,157—1,1571,315Total operating expenses29,84127,09725,844108,391104,552Income from operations1,5223,0031,3799,526669Other income and expense, net14515991431523Income before provision for income taxes1,6673,1621,4709,9571,192Provision for income taxes9951,8869135,065748Net income $
672$
1,276$
557$
4,892$
444Net income per share:Basic$
0.02$
0.04$
0.02$
| SOURCE Omnicell, Inc. Copyright©2010 PR Newswire. All rights reserved |